News | July 04, 2023
SHL Medical acquires 100% of the shares in LCA Automation
SHL Medical announces the acquisition of LCA Automation AG, a Swiss innovative automation solutions provider
SHL Medical announces the acquisition of LCA Automation AG, a Swiss innovative automation solutions provider
The zero-observation outcome reflects the company's robust quality management systems and commitment to excellence in its operations.
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
The VITA-FAST tokens have been met with overwhelming interest
The €70 million investment will allow the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons
The company is already marketing the 4 mg and 10 mg strengths
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement
Subscribe To Our Newsletter & Stay Updated
